• Something wrong with this record ?

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

S. Delimpasi, MA. Dimopoulos, J. Straub, A. Symeonidis, L. Pour, R. Hájek, C. Touzeau, VK. Bhanderi, JG. Berdeja, P. Pavlíček, JV. Matous, PJ. Robak, K. Suryanarayan, A. Miller, M. Villarreal, D. Cherepanov, JK. Srimani, H. Yao, R. Labotka, RZ. Orlowski

. 2024 ; 99 (9) : 1746-1756. [pub] 20240610

Language English Country United States

Document type Journal Article, Clinical Trial, Phase II, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24019155

Grant support
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging. We report the final analysis of a single-arm, phase 2 study evaluating the oral proteasome inhibitor (PI) ixazomib combined with daratumumab and dexamethasone (IDd; NCT03439293). Sixty-one RRMM patients (ixazomib/daratumumab-naïve; 1-3 prior therapies) were enrolled to receive IDd (28-day cycles) until disease progression/unacceptable toxicity. Median age was 69 years; 14.8% of patients had International Staging System stage III disease; 14.8% had received three prior therapies. Patients received a median of 16 cycles of IDd. In 59 response-evaluable patients, the overall response rate was 64.4%; the confirmed ≥very good partial response (VGPR) rate (primary endpoint) was 30.5%. Rates of ≥VGPR in patient subgroups were: high-risk cytogenetics (n = 15, 26.7%), expanded high-risk cytogenetics (n = 24, 29.2%), aged ≥75 years (n = 12, 16.7%), lenalidomide-refractory (n = 21, 28.6%), and prior PI/IMiD therapy (n = 58, 31.0%). With a median follow-up of 31.6 months, median progression-free survival was 16.8 months (95% confidence interval: 10.1-23.7). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 54.1% of patients; 44.3% had serious TEAEs; TEAEs led to dose modifications/reductions/discontinuations in 62.3%/36.1%/16.4%. There were five on-study deaths. Any-grade and grade ≥3 peripheral neuropathy occurred in 18.0% and 1.6% of patients. Quality of life was generally maintained throughout treatment. IDd showed a positive risk-benefit profile in RRMM patients and was active in clinically relevant subgroups with no new safety signals.

Clinical Research Takeda Development Center Americas Inc Lexington Massachusetts USA

Colorado Blood Cancer Institute and Sarah Cannon Research Institute Denver Colorado USA

Department of Haematooncology University Hospital Ostrava and Department of Haematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Hematology and Bone Marrow Transplantation Unit General Hospital Evangelismos Athens Greece

Department of Hematology Medical University of Lodz and Copernicus Memorial Hospital Lodz Poland

Department of Hematology University General Hospital of Patras Patras Greece

Department of Internal Medicine and Hematology University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Internal Medicine Hematology University Hospital Prague Czech Republic

Departments of Lymphoma Myeloma and Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA

Florida Cancer Specialists Tallahassee Cancer Center Tallahassee Florida USA

Global Evidence and Outcomes Lexington Massachusetts USA

Hematology and Medical Oncology Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens Greece

Oncology Clinical Research Takeda Development Center Americas Inc Lexington Massachusetts USA

Oncology Takeda Development Center Americas Inc Lexington Massachusetts USA

Precision and Translational Medicine Takeda Development Center Americas Inc Lexington Massachusetts USA

Quantitative Clinical Pharmacology Takeda Development Center Americas Inc Lexington Massachusetts USA

Sarah Cannon Research Institute Nashville Tennessee USA

Statistics Takeda Development Center Americas Inc Lexington Massachusetts USA

University Hospital Hôtel Dieu Nantes France

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019155
003      
CZ-PrNML
005      
20241024111727.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27382 $2 doi
035    __
$a (PubMed)38856176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Delimpasi, Sosana $u Department of Hematology and Bone Marrow Transplantation Unit, General Hospital Evangelismos, Athens, Greece $1 https://orcid.org/0000000175237510
245    10
$a Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma / $c S. Delimpasi, MA. Dimopoulos, J. Straub, A. Symeonidis, L. Pour, R. Hájek, C. Touzeau, VK. Bhanderi, JG. Berdeja, P. Pavlíček, JV. Matous, PJ. Robak, K. Suryanarayan, A. Miller, M. Villarreal, D. Cherepanov, JK. Srimani, H. Yao, R. Labotka, RZ. Orlowski
520    9_
$a Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging. We report the final analysis of a single-arm, phase 2 study evaluating the oral proteasome inhibitor (PI) ixazomib combined with daratumumab and dexamethasone (IDd; NCT03439293). Sixty-one RRMM patients (ixazomib/daratumumab-naïve; 1-3 prior therapies) were enrolled to receive IDd (28-day cycles) until disease progression/unacceptable toxicity. Median age was 69 years; 14.8% of patients had International Staging System stage III disease; 14.8% had received three prior therapies. Patients received a median of 16 cycles of IDd. In 59 response-evaluable patients, the overall response rate was 64.4%; the confirmed ≥very good partial response (VGPR) rate (primary endpoint) was 30.5%. Rates of ≥VGPR in patient subgroups were: high-risk cytogenetics (n = 15, 26.7%), expanded high-risk cytogenetics (n = 24, 29.2%), aged ≥75 years (n = 12, 16.7%), lenalidomide-refractory (n = 21, 28.6%), and prior PI/IMiD therapy (n = 58, 31.0%). With a median follow-up of 31.6 months, median progression-free survival was 16.8 months (95% confidence interval: 10.1-23.7). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 54.1% of patients; 44.3% had serious TEAEs; TEAEs led to dose modifications/reductions/discontinuations in 62.3%/36.1%/16.4%. There were five on-study deaths. Any-grade and grade ≥3 peripheral neuropathy occurred in 18.0% and 1.6% of patients. Quality of life was generally maintained throughout treatment. IDd showed a positive risk-benefit profile in RRMM patients and was active in clinically relevant subgroups with no new safety signals.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $7 D009101
650    12
$a sloučeniny boru $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D001896
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D000971
650    _2
$a lidé středního věku $7 D008875
650    12
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003907
650    12
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000911
650    12
$a glycin $x analogy a deriváty $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005998
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dimopoulos, Meletios A $u Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece $1 https://orcid.org/0000000189903254
700    1_
$a Straub, Jan $u Department of Internal Medicine - Hematology, University Hospital, Prague, Czech Republic
700    1_
$a Symeonidis, Argiris $u Department of Hematology, University General Hospital of Patras, Patras, Greece $1 https://orcid.org/0000000236853473
700    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Hájek, Roman $u Department of Haematooncology, University Hospital Ostrava and Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Touzeau, Cyrille $u University Hospital Hôtel Dieu, Nantes, France
700    1_
$a Bhanderi, Viralkumar K $u Florida Cancer Specialists, Tallahassee Cancer Center, Tallahassee, Florida, USA
700    1_
$a Berdeja, Jesus G $u Sarah Cannon Research Institute, Nashville, Tennessee, USA $1 https://orcid.org/0000000343620376
700    1_
$a Pavlíček, Petr $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Matous, Jeffrey V $u Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, Colorado, USA
700    1_
$a Robak, Pawel J $u Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
700    1_
$a Suryanarayan, Kaveri $u Clinical Research, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Miller, Alison $u Statistics, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Villarreal, Miguel $u Oncology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Cherepanov, Dasha $u Global Evidence and Outcomes (GEO), Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Srimani, Jaydeep K $u Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Yao, Huilan $u Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Labotka, Richard $u Oncology Clinical Research, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Orlowski, Robert Z $u Departments of Lymphoma/Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 9 (2024), s. 1746-1756
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38856176 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111720 $b ABA008
999    __
$a ok $b bmc $g 2201781 $s 1231128
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 9 $d 1746-1756 $e 20240610 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$p Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options